The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual Function

Phase

N/A

Condition

Enuresis

Urinary Incontinence

Interstitial Cystitis

Treatment

N/A

Clinical Study ID

NCT05391425

solifenacinpm

Ages 18-90
Female

Study Summary

This study aims to determine whether Solifenacine used for lower urinary tract symptoms improves sexual function and if so does this improvement differs between premenopausal and postmenopausal women.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Women presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinarytract symptoms that are planned to start treatment with Solifenacin 5 mg (Vesicare 5mg).
Patients agreed to involve in the study, having discussed other treatment options andpossible side effects of the medication.
Informed consent obtained

Exclusion

Exclusion Criteria:

urinary tract infection
stress urinary incontinence
urinary retention
grade 2 or above pelvic organ prolapse according to POP-Q scale
Solifenacin contraindications such as narrow angle glaucoma, allergy of Solifenacin orother components of the drug.

Study Design

June 03, 2021

June 03, 2024

Study Description

Solifenacin is an anticholinergic drug that is commonly used for lower urinary tract symptoms such as urgency, frequency and urge urinary incontinence. Solifenacin use and sexual function improvement is presented in some research, but the correlation between the improvement in sexual function and LUTS symptoms is yet not investigated. Also the effect on sexual function in premenopausal vs postmenopausal women are unknown.

Connect with a study center

Arnavutkoy State Hospital
Istanbul, Arnavutkoy 34275
Turkey
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.